Antisense telomerase induced cell growth inhibition, cell cycle arrest and telomerase activity down-regulation in gastric and colon cancer cells

Anticancer Research

Volumn 23, Issue 1 A, 2003, Pages 465-469

  Wong, Stephen C H ^a   Yu, Hanry ^a   Moochhala, Shabbir M ^b   So, Jimmy B Y ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DEFENCE SCIENCE AND TECHNOLOGY AGENCY   (Singapore)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Antisense telomerase; Apoptosis; Cell cycle arrest; Telomerase activity

Indexed keywords

COMPLEMENTARY RNA; TELOMERASE; TELOMERASE INHIBITOR;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL GROWTH; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ENZYME ACTIVITY; ENZYME REGULATION; HISTOGRAM; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; STOMACH CANCER; TELOMERIC REPEAT AMPLIFICATION PROTOCOL;

ADENINE NUCLEOTIDES; APOPTOSIS; CELL CYCLE; CELL DIVISION; COLONIC NEOPLASMS; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGORIBONUCLEOTIDES; RNA, ANTISENSE; STOMACH NEOPLASMS; TELOMERASE; TRANSFECTION;

EID: 0037231219     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
2. Zhang DK, Ngan BY, Cheng RY, Cheung AN, Liu SS and Tsao SW: Clinical significance of telomerase activation and telomeric restriction fragment (TRF) in cervical cancer. Eur J Cancer 35: 154-160, 1999.
3. Cheng RY, Yuen PW, Nicholls JM, Zheng Z, Wei W, Sham JS, Yang XH, Cao L, Huang DP and Tsao SW: Telomerase activation in nasopharyngeal carcinomas. Br J Cancer 77: 456-460, 1998.
4. White LK, Wright WE and Shay JW: Telomerase inhibitors. Trends Biotechnol 19: 114-120, 2001.
5. Kondo S, Kondo Y, Li G, Silverman RH and Cowell JK: Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 16: 3323-3330, 1998.
6. Mukai S, Kondo Y, Koga S, Komata T, Barna BP and Kondo S: 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res 60: 4461-4467, 2000.
7. Zhou A, Hassel BA, and Silverman RH: Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. Cell 72: 753-765, 1993.
8. Torrence PF, Maitra RK, Lesiak K, Khamnei S, Zhou A and Silverman RH: Targeting RNA for degradation with a (2′-5′)oligoadenylate - antisense chimera. Proc Natl Acad Sci USA 90: 1300-1304, 1993.
9. Kushner DM, Paranjape JM, Bandyopadhyay B, Crarner H, Learnan DW, Kennedy AW, Silverman RH and Cowell JK: 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Gynecol Oncol 76: 183-192, 2000.
10. Komata T, Kondo Y, Koga S, Ko SC, Chung LW and Kondo S: Combination therapy of malignant glioma cells with 2-5A - antisense telomerase RNA and recombinant adenovirus p53. Gene Ther 7: 2071-2079, 2000.
11. Kondo Y, Koga S, Komata T and Kondo S: Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene 19: 2205-2211, 2000.
12. Koga S, Kondo Y, Komata T and Kondo S: Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. Gene Ther 8: 654-658, 2001.
13. Kondo Y, Komata T and Kondo S: Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. Int J Oncol 18: 1287-1292, 2001.
14. Torrence PF, Xiao W, Li G, Crarner H, Player MR and Silverman RH: Recruiting the 2-5A system for antisense therapeutics. Antisense Nucleic Acid Drug Dev 7: 203-206, 1997.
15. Yasui W, Oue N, Kuniyasu H, Ito R, Tahara E and Yokozaki H: Molecular diagnosis of gastric cancer: present and future. Gastric Cancer 4: 113-121, 2001.
16. Gordon D: Revising theories of colon carcinogenesis: telomeres and colon cancer models. Gastroenterology 119: 891-892, 2000.
17. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adarns RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Greider CW and Villeponteau B: The RNA component of human telomerase. Science 269: 1236-1241, 1995.
18. Zhang RG, Wang XW, Yuan JH and Xie H: Human hepatoma cell telomerase activity inhibition and cell cycle modulation by its RNA component antisense oligodeoxyribonucleotides. Acta Pharmacol Sin 21: 742-746, 2000.
19. Kondo S, Tanaka Y, Kondo Y, Hitomi M, Barnett GH, Ishizaka Y, Liu J, Haqqi T, Nishiyama A, Villeponteau B, Cowell JK and Bama BP: Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. Faseb J 12: 801-811, 1998.
20. Kyo S and Inoue M: Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy? Oncogene 21: 688-697, 2002.
21. Corey DR: Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene 21: 631-637, 2002.
22. Galderisi U, Cascino A and Giordano A: Antisense oligonucleotides as therapeutic agents. Cell Physiol 181: 251-257, 1999.